Proceeds From Chagas Treatment Priority Review Voucher Will Help Ensure Access
Executive Summary
US FDA approved its first treatment for the tropical disease and awarded a priority review voucher that will be sold as per agreement between development partners.
You may also be interested in...
Priority Review Voucher Fee Rises 4.6% For Fiscal 2018
As of Oct. 1, the fee for rare pediatric disease and tropical disease priority review vouchers will be $2.83m; the increase follows a slight decline in FY 2017.
Keeping Track: US FDA's Late Summer Approval Extravaganza Stars Three Novel Agents, Features Return Of Mylotarg
Kymriah, Vabomere, and benzidazole approvals joined by new indications for Austedo, Faslodex.
FDA's NDA And BLA Approvals: Kymriah, Vabomere, Cyltezo
Original new drugs and biologics recently approved by US FDA.